PROGENRA, INC.

Basic Information

271A GREAT VALLEY PKWY
271A GREAT VALLEY PKWY
MALVERN, PA, 19355-

Company Profile

n/a

Additional Details

Field Value
DUNS: 190641816
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Ubiquitin pathway inhibitors for treatment of asthma

    Amount: $222,380.00

    DESCRIPTION (provided by applicant): Asthma is a chronic disease with considerable morbidity and no cures. Symptomatic treatment is efficacious but produces significant adverse effects. Thus, improved ...

    SBIR Phase I 2014 Department of Health and Human Services
  2. Chemical optimization of a novel class of USP7 inhibitor for cancer treatment

    Amount: $224,974.00

    DESCRIPTION (provided by applicant): Many regulatory proteins are themselves tightly controlled by ubiquitin conjugating and deconjugating enzymes, whose dysfunctional forms are implicated in numerous ...

    SBIR Phase I 2014 Department of Health and Human Services
  3. Ubiquitin based therapy of aggressive cancer cell populations

    Amount: $224,768.00

    DESCRIPTION (provided by applicant): The degradation of most cellular proteins is regulated by coordinated addition and removal of ubiquitin by families of ubiquitin E3 ligases and deubiquitylating en ...

    SBIR Phase I 2014 Department of Health and Human Services
  4. Development of selective substrate based inhibitors of ubiquitin isopeptidases

    Amount: $224,379.00

    DESCRIPTION (provided by applicant): The FDA approval of the proteasome inhibitor bortezomib/VELCADE(r) for the treatment of multiple myeloma and other hematological malignancies demonstrates that the ...

    SBIR Phase I 2014 Department of Health and Human Services
  5. Novel treatment for Huntington???s Disease

    Amount: $224,512.00

    DESCRIPTION (provided by applicant): Because of their degeneracy and selective involvement in most cellular pathways, ubiquitin conjugating and deconjugating enzymes are being explored as therapeutic ...

    SBIR Phase I 2014 Department of Health and Human Services
  6. Identification of natural products to treat neoplastic disease

    Amount: $342,963.00

    DESCRIPTION (provided by applicant): As in the past, most new FDA-approved drugs for cancer and other indications are derived from natural products or inspired by natural products. Accordingly, it is ...

    SBIR Phase I 2012 Department of Health and Human Services
  7. Ubiquitin E3 ligase detection by fluorescence resonance transfer

    Amount: $263,031.00

    DESCRIPTION (provided by applicant): Because of its involvement in a broad range of cellular signal transduction and other mechanisms, the ubiquitin pathway is now recognized as a new opportunity for ...

    SBIR Phase I 2012 Department of Health and Human Services
  8. Novel molecular therapeutics for cystic fibrosis

    Amount: $282,804.00

    DESCRIPTION (provided by applicant): Approximately 70,000 individuals worldwide suffer from the debilitating disease cystic fibrosis (CF), which typically is fatal owing to sepsis in the abnormally v ...

    SBIR Phase I 2012 Department of Health and Human Services
  9. Selective inhibitors of ubiquitin E3 ligase to treat high cholesterol

    Amount: $296,751.00

    DESCRIPTION (provided by applicant): Hypercholesterolemia is a major factor in cardiovascular disease. In the USA, more than 35 million individuals have high total cholesterol and thus twice the norma ...

    SBIR Phase I 2011 Department of Health and Human Services
  10. USP34 as a novel target for treatment of idiopathic pulmonary fibrosis

    Amount: $265,823.00

    DESCRIPTION (provided by applicant): Aberrant overactivation of WNT signaling appears to play a major role in Idiopathic Pulmonary Fibrosis (IPF). Inhibitors of overactivated WNT signaling are candida ...

    SBIR Phase I 2010 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government